Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Gross Profit (2020 - 2025)

Gyre Therapeutics (GYRE) has disclosed Gross Profit for 6 consecutive years, with $28.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit rose 17.96% to $28.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $102.4 million, a 1.32% increase, with the full-year FY2024 number at $101.9 million, down 6.38% from a year prior.
  • Gross Profit was $28.9 million for Q3 2025 at Gyre Therapeutics, up from $25.6 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $48.1 million in Q4 2022 to a low of -$52000.0 in Q4 2021.
  • A 5-year average of $19.7 million and a median of $24.5 million in 2024 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: tumbled 157.14% in 2021, then skyrocketed 595250.0% in 2023.
  • Gyre Therapeutics' Gross Profit stood at -$52000.0 in 2021, then soared by 92515.38% to $48.1 million in 2022, then crashed by 46.11% to $25.9 million in 2023, then rose by 3.08% to $26.7 million in 2024, then increased by 8.39% to $28.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Gross Profit are $28.9 million (Q3 2025), $25.6 million (Q2 2025), and $21.2 million (Q1 2025).